13 results about "Cardiac ischaemia" patented technology

The invention discloses application of 9 ''-salvianolic acid B monomethyl ester in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of biological medicine. The CAS number of the 9 ''-salvianolic acid B monomethyl ester is 1167424-31-8, the ischemic heart disease refers to myocardial injury induced by heart ischemia reperfusion, and the invention further provides a pharmaceutical composition or a small molecule injection preparation. Animal experiments show that 9 ''-salvianolic acid B monomethyl ester is exogenously injected to relieve myocardial injury of a mouse and improve the heart function of the mouse, and it is proved that the medicine containing 9''-salvianolic acid B monomethyl ester can improve the ischemic heart disease, especially myocardial injury caused by heart ischemia reperfusion, and has a good application prospect. The invention provides potential drug selection and research direction for preventing and treating ischemic heart disease, and has important clinical application value.

Systems and Methods are disclosed for detecting acute coronary syndrome (ACS) events, arrythmias, heart rate abnormalities, medication problems such as non-compliance or ineffective amount or type of medication, and demand / supply related cardiac ischemia. The system may have both implanted and external components that communicate with a Physicians's programmer, and smart-devices for monitoring and alerting to detected medically relevant events or states. At least one processor provides event detection using statistical threshold criteria calculated upon at least a portion of a patient's data / distributions and set for a patient or based upon what a doctor determines as abnormal for a patient. A power management system provides at least 2 strategies of evaluating power level including at least obtaining a voltage measure and measuring and calculating a cumulative capacity measure and comparing these two measure to their respective thresholds.

Reganoxonin is used in the preparation of a drug for the detection of ischemic heart disease by echocardiography. Echocardiography is selected from one or more of stress echocardiography, myocardial angiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. Ischemic heart disease is selected from one or more of non-obstructive or obstructive ischemic heart disease. The diagnosis of the patient's disease by administering the drug has good accuracy, sensitivity, specificity, and safety.

The present invention relates to an injectable hydrogel loaded with targeted engineered extracellular vesicles, as well as its preparation method and application, and belongs to biomedical engineering. The present invention provides an injectable hydrogel loaded with targeted engineered extracellular vesicles, wherein the injectable hydrogel is a GelMA hydrogel loaded with ischemia-targeted miR222-engineered extracellular vesicles; the ischemia-targeted miR222-engineered extracellular vesicles overexpress miR222 and are surface-modified with a targeting polypeptide. The injectable hydrogel loaded with targeted engineered extracellular vesicles can be minimally invasively injected into the pericardial cavity to form a cardiac patch and improve cardiac ischemia-reperfusion injury.

This disclosure provides methods for treating ischemic reperfusion injury. In particular, provided herein are methods for reducing the effects of and / or treating cardiac ischemic reperfusion injury comprising administering a therapeutic composition (e.g., an angiotensin derivative polypeptide). In some embodiments, the method comprises administering an angiotensin derivative polypeptide to a subject during, and / or after a cardiac ischemic event.

The invention discloses a mitochondrial delivery system of macrophages in a targeted heart ischemia reperfusion injury area as well as a preparation method and application of the mitochondrial delivery system, and relates to the technical field of biomedical engineering. The mitochondrial delivery system comprises an active mitochondrial and a physiological platelet coupled to the surface of the active mitochondrial and capable of expressing a membrane protein P-selectin. The mitochondrial delivery system provided by the invention can be adhered to the surface of circulating monocytes through physiological platelet membrane protein P-selectin, recruits by virtue of inflammatory cells, and is accurately targeted to the aggregation part of monocytes and macrophages of ischemic myocardium; and then active mitochondria is transplanted to the inflammatory macrophages to achieve the effect of relieving the heart ischemia reperfusion injury, so that the defects of the existing mitochondria targeting delivery technology are partially solved, the potential influence on other healthy organs can be avoided while the myocardial ischemia reperfusion injury is relieved, the side effect is reduced, and the clinical application prospect is broad. The efficient delivery of active mitochondria is realized.

Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

The invention belongs to the technical field of biology, and relates to application and products of a snoRNA-Snord11 gene and a Snord11 gene inhibitor. When the heart ischemia reperfusion injury occurs, the mRNA expression level of the Snord11 is remarkably up-regulated and is highly related to the myocardial cell ferroptosis, and the occurrence of the myocardial cell ferroptosis can be remarkably inhibited by silencing the Snord11. The Snord11 gene provided by the invention can be used as a diagnostic marker and a therapeutic target of the heart ischemia-reperfusion injury, and the knock-down of Snord11 gene expression effectively alleviates the problems of poor prognosis of patients with the ischemia-reperfusion injury and heart disease treatment. The Snord11 gene inhibitor can be used as a therapeutic drug of the Snord11 gene inhibitor, and a new basis is provided for poor prognosis and heart disease treatment of patients suffering from heart ischemia-reperfusion injury.

The invention belongs to the technical field of medicines, and discloses an oxo aromatic heterocyclic derivative as well as a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention relates to an oxo aromatic heterocyclic derivative shown as a general formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a preparation method thereof, and a composition containing one or more of the compounds. The invention also relates to application of the compounds in treatment of CD73-related diseases such as tumors, cancers, inflammation-related diseases, immune-related diseases, nervous system diseases, neurodegenerative diseases, central nervous system diseases, depression, Parkinson's disease, sleep disorders and fibrosis and cerebral and cardiac ischemic diseases.

Disclosed are non-natural peptides useful for treating and preventing ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

The present invention pertains to the technical field of medicines. Disclosed are a class of oxoaromatic heterocyclic derivatives, preparation methods therefor, pharmaceutical compositions thereof, and use thereof. Specifically, the present invention relates to a class of oxoaromatic heterocyclic derivatives represented by general formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, preparation methods therefor, compositions comprising one or more of the compounds, and use of the compounds in the treatment of CD73-related diseases, such as tumors, cancer, inflammation-related diseases, immune diseases, diseases of the nervous system, neurodegenerative diseases, diseases of the central nervous system, depression, Parkinson's disease, sleep disorders, fibrosis, and cerebral and cardiac ischemic diseases.

The invention relates to compositions and methods for reducing ischemia-reperfusion injury. In certain embodiments, therapeutic compositions and methods for preventing, inhibiting, alleviating or treating cardiac ischemia-reperfusion injury are provided. The therapeutic compositions may comprise a variety of microRNA (miR) antagonists. In certain embodiments, the methods include administering a therapeutic composition to a subject before, during, and / or after a cardiac ischemic event. The method may include ischemic heart tissue reperfusion.

The application provides application of a small molecule compound S89 in preparation of a drug for treating diseases related to mitochondrial abnormalities, and belongs to the field of medicines. The small molecule compound S89 can enhance the enzyme activity of mitochondrial MFN1 protein, has the effects of promoting mitochondrial fusion of cells, restoring mitochondrial morphology and function, and can improve axon degeneration of motor neurons of CMT2A patients, and can be used for preparing a drug for treating CMT2A type Charcot-Marie-Tooth disease and a heart ischemia-reperfusion injury syndrome, and can also be used for preparing a drug for inhibiting proliferation of lung cancer cells.